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Summary The influence of a new aromatase inhibitor, CGS 16949A on peripheral aromatisation of andro-
stenedione into oestrone was investigated in postmenopausal women with breast cancer. A mixture of 3H
androstenedione and 14C oestrone was injected, and all urine was collected for the following 96 h. The isotope
ratio was determined in the urinary oestrogen metabolites after isolation by HPLC. Eight patients were
investigated before and during treatment with CGS 16949A. At a dose of 1 mg b.d. (eight patients) CGS
16949A inhibited aromatisation by a mean value of 82.4% (range 71.3 to 93.7%). When the drug dose was
escalated to 2 mg b.d. (three patients) aromatisation was inhibited by a mean of 92.6% (range 90.6 to 95.8%).
these results suggest that CGS 16949A at a dose of 1 mg b.d. causes submaximal aromatase inhibition in many
patients, while a dose of 2 mg b.d. seems to result in greater than 90% aromatase inhibition. These data are
consistent with previous observations that the higher dose is more effective in suppression of plasma oestradiol
levels.
The majority of endocrine treatments of breast cancer act by
reducing oestrogenic stimulation of the tumour cell. This can
be achieved by (1) suppressing the supply of oestrogen to the
tumour cell or (2) blocking oestrogen action at the cellular
level by administration of oestrogen receptor antagonists
such as tamoxifen.
The main pathway of oestrogen production in postmeno-
pausal women is peripheral conversation of androstenedione
into oestrone, which is called aromatisation because of con-
version of the A- ring of the androgen to the aromatic A-
ring of oestrogens (Grodin et al., 1973). In 1978 Santen and
co-workers (Santen et al., 1978) demonstrated that this con-
version could be inhibited by the drug aminoglutethimide in
vivo. This finding introduced aromatase inhibition as a new
therapeutic approach for postmenopausal breast cancer.
Breast cancer patients treated with aminoglutethimide
achieve response rates similar to that obtained with tamoxi-
fen (L0nning & Kvinnsland, 1988). However, as aminoglute-
thimide causes several side effects, much effort is currently
being spent on the development of alternative aromatase
inhibitors for clinical use (L0nning et al., 1990).
CGS 16949A (Ciba-Geigy Pharmaceuticals) is a potent
new aromatase inhibitor which causes regression of DMBA-
induced mammary tumours in rats (Schieweck et al., 1988)
and has now been investigated in phase I clinical trials
(Lipton et al., 1990; Stein et al., 1990). In vitro studies have
shown this drug to inhibit aromatisation at drug concentra-
tions 200-400 fold lower than the concentration of amino-
glutethimide needed to produce the same effect (Steele et al.,
1987). Recent investigations reported plasma and urine
oestrogens to be suppressed in patients treated with CGS
16949A, but there is disagreement about the dose relation-
ship (Santen et al., 1989; Dowsett et al., 1990; Klepp et al.,
1990).
Although suppression of plasma oestrogen levels may be
the determinant of the tumour response it is important to
recognise that changes in these levels cannot indicate whether
it is synthesis or metabolic clearance of the oestrogen(s) or a
combination of the two which is affected. For example,
recent results suggest enhancement of oestrogen metabolism
could be partly responsible for the suppression of plasma
oestrogen levels by aminoglutethimide (L0nning et al., 1987;
L0nning et al., 1989b). Therefore, while the finding that CGS
16949A suppresses plasma oestrogen levels suggests that the
drug acts as an aromatase inhibitor in vivo, the exact mech-
anism behind the changes in plasma oestrogen levels can only
be assessed from in vivo tracer studies. Thus, this study was
initiated to evaluate the influence of CGS 16949A on aroma-
tisation of androstenedione (A) into oestrone (El) in vivo.
Patients, materials and methods
Patients
The protocol was approved by the Ethical Committee at the
Royal Marsden Hospital. Eight postmenopausal breast
cancer patients who were to receive treatment with CGS
16949A for progressive breast cancer were enrolled in the
study. All patients gave their informed consent to participate.
Their mean age was 64.9 years (46-76 year), mean body
weight was 68.9 kg (57.5-87.5). Seven of the patients having
undergone a spontaneous menopause, the youngest one hav-
ing received previous treatment with buserelin followed by
oophorectomy. All patients had been treated with tamoxifen
previously. Two patients had also received previous treat-
ment with aminoglutethimide (more than 1 year before), one
patient had received MPA and one patient buserelin. No
systemic anticancer treatment was given for the last 4 weeks
before initiation of this investigation.
Chemicals
All solvents were of analytical or HPLC grade and obtained
from BDH. [6,7-3H]A (41 Ci mmole-') was a gift from Ciba-
Geigy Pharmaceuticals, Horsham, Sussex (courtesy Dr R.
Wade). [4-'4C]E, (50-60mCimmole-') was obtained from
New England Nuclear (Dreiech, Germany). DEAE-Sephadex
was obtained from Pharmacia Ltd (Uppsala, Sweden).
Investigation protocol
Intravenous bolus injections of a mixture of [6,7-3H]andro-
stenedione and [4-14C]oestrone were followed by measure-
ment of isotope ratios in oestrogen metabolites in urine
collected over the subsequent 96 h.
In vivo aromatisation was investigated before and follow-
ing 4-8 weeks on treatment with CGS 16949A 1 mg b.d.
Three patients had a further dose escalation to 2 mg b.d.,
4-8 weeks after which a third tracer injection was given. On
each occasion, the patient received a bolus injection of
[6,7-3H]A (500pCi) and [4-'4C]E, (5gCi) concurrently. The
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tracers were dissolved in a total volume of 54 ml of
saline:ethanol (92:8 w/w). Due to a high ratio between 3H
and "C DPM in the injection vehicle, this was prepared and
the amount of tracer measured according to a strict protocol
to avoid misreading of 3H in the "'C channel during the
measurement of isotope ratios: 5 tCi of [4-'4C]E, in 3.5 ml of
ethanol was added to 50 ml of saline. From this solution four
aliquots of 50fil each were obtained for estimation of the '4C
in the injection mixture by liquid scintillation counting.
[6,7-3H]A was added in 0.5 ml of ethanol, and another four
50 jlI aliquots of the solution were obtained for estimation of
the 3H component of the injection mixture. Fifty ml of this
solution was aspirated into a glass syringe, and administered
as a 10 min i.v. bolus injection through a teflon cannula.
Urine was collected for 4 days after injection. The sample
was mixed, its total volume measured, and two aliquots of
800 ml each frozen and stored at - 20°C until analysis.
Table I Example of interassay variation for samples obtained from
one patient (No. 2) for the control and on treatment
(CGS 16949A 1 mg b.d.)
Control situation CGS 16949A I mg b.d.
3H '4C 3H '#C
DPM DPM 3H/'4C DPM DPM 3H/'4C
Oestrone
Run 1 4490 2999 1.50 846 1394 0.61
Run 2 8007 5415 1.48 881 1595 0.55
Oestradiol
Run 1 553 326 1.70 n.d. n.d.
Run 2 928 631 1.47 n.d. n.d.
Oestriol
Run 1 4029 2653 1.52 1417 2652 0.53
Run 2 5742 3845 1.49 1305 2452 0.53
n.d. - not detectable; % Inhibition of aromatisation: run 1 - 73.15;
run 2 - 72.66.
Urine analysis
A detailed description of the analytical method and its repro-
ducibility is given elsewhere (Jacobs et al., 1990). Briefly, the
analysis is conducted as follows:
Urine samples (800 ml) were thawed and the steroid glucu-
ronides concentrated by use of Sep-Pak C18 cartridges
followed by chromatography on a DEAE Sephadex column
eluted by a salt gradient. The salts were eliminated by further
chromatography on C18 Sep-Pak columns. Hydrolysis was
performed at 37°C for 48 h with 1 ml (144,000 units) P-
glucuronidase (Sigma, G-8885). Following extraction, the
hydrolysed oestrogens were separated from androgens by a
two-step anion exchange chromatography process using
DEAE-Sephadex. Thereafter, oestrone (E,), oestradiol (E2)
and oestriol (E3) were isolated by HPLC using a Hypersil
ODS 5 1t (Chrompack) 4.6 x 250 mm column and a mobile
phase of acetonitrile/phosphate buffer 0.05 M pH 3 (L0nning
et al., 1989c; Jacobs et al., 1990). Due to the high level of
3H-labelled androgens in the urine it was not possible to
measure the recovery of oestrogen metabolites during these
analytical steps. However, since between 50 and 70% of
"C-labelled oestrogens administered are recovered in a
72-96 h urine sample (Fishman et al., 1966; Zumoff et al.,
1968), the overall recovery may be estimated as about
35-50%.
Liquidscintillation counting
All samples were counted in a Tricarb 1990CA liquid scintil-
lation counter using automatic quench calibration. Each sam-
ple was counted in a 10 ml plastic vial with Emulsifier Safe
(Packard) scintillation fluid. Under these conditions, the
computer program caused between 0.2 and 0.4% of 3H to be
read in the 14C channel but no 14C in the 3H channel.
When repeat analyses were conducted on samples obtained
in control and on-treatment situations, interassay coefficients
of variation for all three metabolites were found to be less
than 5% (Jacobs et al., 1991). An example of samples sub-
jected to repeat analysis from one patient (No. 2) from both
control and on-treatment situations is given in Table I.
Pharmacokinetic calculations
The extent of in vivo aromatisation was calculated from the
formula:
% aromatisation=
('H/"4C) urine metabolite x 100/(3H/14C) injection mixture
Results
Typical radiochromatograms of urine samples obtained in
the control situation and after 4 weeks on CGS 16949A
treatment are shown in Figures 1 and 2 respectively. The
parallel nature of 'H and 14C in the peaks corresponding to
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Figure 1 Radiochromatogram of urinary oestrogens separated
by HPLC in a urinary sample obtained in the control situation.
E3 is oestriol, E2 is oestradiol and E, is oestrone.
the separated oestrogens is clear. Lack of radioactivity in the
area of the chromatogram corresponding to catechol oestro-
gens (between E2 and El) suggests that these metabolites have
probably been destroyed during the analytical process
because no antioxidants were used (L0nning et al., 1989c).
The inclusion of an antioxidant such as ascorbic acid would
have interfered with the anion exchange chromatography
prior to HPLC.
Aromatisation of A to El in the eight patients before
commencing on CGS 16949A treatment is shown in Figure 3.
The percentage of aromatisation is obtained separately from
the isotope ratio in the E,, E2 and E3 fraction. It can be seen
that there is a relatively close agreement between the results
obtained from the different oestrogen metabolites for each
patient.
The isotope ratio could be determined in both the El and
E3 fractions in the treatment as well as the control situation
in all patients. However, while the isotope ratio in the E2
fraction could be determined in all patients in the control
_
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Table II Percentage aromatase inhibition measured from urinary
isotope ratio ofoestriol (E3) and oestrone (El), with the mean value of
the two oestrogen metabolites for patients treated with CGS 16949A
1mg b.d. and 2mg b.d.
CSG 16949A I mg b.d. CGS 16949A 2mg b.d.
Patient E3 E, Mean E3 E, Mean
1 82.9 84.1 83.5
2 74.0 70.5 72.3
3 86.2 83.7 85.0
4 78.4 73.8 76.1 98.2 93.4 95.8
5 87.1 83.7 85.4
6 91.3 91.1 91.2
7 68.4 74.2 71.3 89.9 91.2 90.6
8 95.5 91.9 93.7 91.7 91.2 91.5
Mean 83.0 81.6 82.4 93.3 91.9 92.6
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Figure 2 Radiochromatogram of urinary oestrogens separated
by HPLC. The same patient as shown in Figure 1, urine obtained
after 4 weeks on treatment with CGS 16949A.
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Figure 3 The percentage of aromatisation of A into El in the
control situation evaluated separately from the isotope ratio in
the E3, E2 and El fractions.
situation, the amount of this metabolite was usually much
lower than the other two, and sometimes too low for quanti-
tation. Therefore, aromatase inhibition was evaluated from
the isotope ratios in the E1 and E3 fractions only.
The percentage by which treatment with CGS 16949A
given as 1 mg b.d. or 2 mg b.d. inhibited aromatisation is
shown in Table II. For the 1 mg b.d. dose, there is a marked
variation in the effectiveness by which this drug schedule
inhibited aromatisation (range 71.3% to 93.7%, mean value
82.4%). Among the three patients who had a dose escalation
to 2 mg b.d., the two who had aromatase inhibition of less
than 90% during treatment with CGS 16949A 1 mg b.d.
achieved a more efficient inhibition on the higher dose. On
the contrary, the one patient who had aromatase inhibition
of more than 90% by the 1 mg b.d. drug schedule experi-
enced no further inhibition after dose escalation to 2 mg b.d.
The possibility was examined that the patients with the
highest initial levels had the most pronounced suppression of
aromatisation. Figure 4 compares the control values of
aromatisation with the percentage of aromatase inhibition
caused by treatment with CGS 16949A 1 mg b.d. As shown,
the degree of aromatase inhibition was not influenced by the
magnitude of the control value.
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Figure 4 Per cent aromatase inhibition (mean value for the
oestrone and oestriol fraction) compared to initial aromatisation
value (mean value for all three oestrogen metabolites).
Discussion
The method used in this investigation provides a reliable
method to measure peripheral aromatisation in vivo, with
intra- and inter-assay coefficients of variation ofless than 5%
(Jacobs et al., 1991). In addition, it provides several advan-
tages compared to other alternative methods.
Firstly, plasma oestrogen levels may vary during the day
(Vermeulen et al., 1976; L0nning et al., 1989a), which could
be related to a time-related variation in aromatisation.
Measuring aromatisation in 4-day collections of urine gives a
mean value of aromatisation over time which avoids any
possible short time influences.
Secondly, plasma tracer studies require a sufficient infusion
time to achieve steady state plasma levels. Plasma El needs to
equilibrate with the EIS pool (L0nning et al., 1989b). EIS has
a slow half-life (about 6 h) and a plasma clearance value of
about 3-7 1 h-' only (Longcope, 1972; Ruder et al., 1972;
L0nning et al., 1987). Thus, it may be difficult to reach a
plasma steady state condition for an El tracer without per-
forming long-term infusions. This problem seems to be of
particular importance in obese patients who seem to have a
slower turnover of their oestrogen pool (Longcope, 1982).
A third problem relates to method sensitivity. In contrast
to E1S, El has a rapid clearance rate about 50-801 h-'
(Longcope & Williams, 1974; L0nning et al., 1989b). Thus, it
may be difficult to administer sufficient tracer doses over a
sufficiently long infusion time to achieve the sensitivity neces-
sary for aromatase measurement in patients treated with
potent enzyme inhibitors.
Fourthly, this method determines the isotope ratio in
different urine metabolites. The possibility exists that some El
produced by aromatisation could be metabolised in the same
compartment before entering the plasma pool. If so, this
fraction would not be detected either by a plasma or a
0
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urinary method measuring the isotope ratio in the El fraction
only, but it would most probably be detected in a urinary
assay measuring the isotope ratio in different metabolites.
Following tracer oestrogen injections urinary radioactivity
is excreted over the next 3 to 4 days (L0nning et al., 1987;
L0nning & Skulstad, 1989). Thus any minor loss of urine
during the sampling period would be expected to have little
impact on the result obtained, in as much as we measured
the isotope ratio and not the total amount of the excreted
metabolites. The isotope ratio was not measured in uncon-
jugated oestrogens or sulphated metabolites since about 90%
of total urinary oestrogen metabolites are excreted as glu-
curonide conjugates (Gurpide, 1978).
It was not possible to isolate catechol oestrogens by this
method. Production of catechol oestrogens (mainly 20H-E1)
and E3 are the two major hydroxylation pathways in oestro-
gen metabolism, and these pathways are considered to be
substrate competitive (Bolt, 1979). Accordingly, any change
in the urinary excretion of the one metabolite would be
expected to result in alterations in the other metabolite. A
consistent isotope ratio in the E3 and El fractions therefore
suggests a consistent ratio between El and the other major
metabolites in general.
Several investigations have confirmed that CGS 16949A
causes oestrogen suppression in postmenopausal breast
cancer patients (Dowsett et al., 1990; Santen et al., 1989;
Klepp et al., 1990), but the results differ somewhat according
to which dose of drug was found to be the lowest necessary
to obtain maximal oestrogen suppression. Santen et al. (1989)
found a drug schedule of 1 mg b.d. to give maximum sup-
pression, whilst Dowsett et al. (1990) reported that plasma
oestradiol levels were suppressed further when the CGS
16949A dose was escalated from 1 mg b.d. to 2 mg b.d. The
classical aromatase inhibitor, aminoglutethimide, was an un-
specific drug, inhibiting several adrenal hydroxylases in addi-
tion to its influence on the aromatase enzyme (Harris et al.,
1983; Vermeulen et al., 1983). CGS 16949A was synthesised
in an attempt to develop a pure aromatase inhibitor. How-
ever, recent results suggest that 16949A inhibits adrenal
secretion of aldosterone in a dose-dependent manner in the
1-2 mg b.d. dose range (Dowsett et al., 1990). Thus, it may
be of clinical importance to determine the minimal drug dose
necessary to achieve optimal aromatase inhibition.
The results of this study show that some patients may have
a less effective inhibition of aromatase with 1 mg b.d. than
with 2 mg b.d. When given at this higher dose, CGS 16949A
caused aromatase inhibition comparable to that previously
reported for aminoglutethimide (Santen et al., 1978; Dowsett
et al., 1985) and 4-hydroxyandrostenedione (Reed et al.,
1990). Thus, the results of this investigation illustrate the
importance of tracer studies to evaluate aromatase inhibitors.
Firstly, it confirms that the drug acts as an aromatase
inhibitor in vivo. Secondly, this method proves to be a
valuable aid to discriminate between the effectiveness of
different doses of an aromatase inhibitor.
As plasma drug levels for CGS 16949A were not available,
it was not possible in this report to assess whether the
variation in aromatase inhibition for the patients treated with
CGS 16949A could be due to variations in plasma drug levels
or variation in drug sensitivity. Most patients treated with a
CGS 16949A drug schedule of 2 mg b.d. will have steady
state plasma drugs concentrations varying between 2 and
lO ng ml-' or 8 and 40 nM (Lipton et al., 1990). Steady state
plasma concentrations of aminoglutethimide in patients
receiving 250 mg or 1000 mg daily are about 400 and 1600-
fold higher respectively (Murray et al., 1979; L0nning et al.,
1985; Stuart-Harris et al., 1985). While in vitro studies have
suggested CGS 16949A to be 200 and 400 times more potent
than aminoglutethimide (Steele et'al., 1987), any comparison
of plasma drug levels should be interpreted with care, as no
information considering tissue drug levels are available.
In conclusion, our results indicate that CGS 16949A given
as a drug schedule of 1 mg b.d. caused submaximal aroma-
tase inhibition in many patients, while the dose of 2 mg b.d.
caused more than 90% aromatase inhibition in each of the
three patients investigated. Together with the clinical results
from phase II trials, this result should provide the basis for
selecting the appropriate dose of CGS 16949A if the drug is
to be considered for phase III comparative trials with estab-
lished agents. The measurement of aromatase inhibition in
vivo is likely to become a benchmark in comparative studies
of aromatase inhibitors. It is important that a sufficiently
sensitive and rugged method such as that described is used to
make the measurements.
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